Ann: CEO Operational Review, page-12

You are correct Birdchirp however I would also temper your assertion that RAP can diagnose anything yet. This has not been proven with any confidence and when you speak with Doctors about diagnosing Chronic Respiratory disease, there are more tests that Doctors go through (i.e. lung function, spirometry etc) to gain a complete picture of the patients physiology. RSH is a clinically proven system that measures the primary symptom of asthma (& other chronic respiratory diseases) which is wheezing.
The differences that need to be understood between RSH & RAP are as follows: -

1. RSH measures wheeze; RAP is trying to measure cough - there are a number of symptoms of asthma in patients of which wheeze is a "primary" symptom (i.e. it is present in the majority of cases) whereas cough in not a primary symptom (i.e. present in only some cases). This is an important difference as the usefulness of RSH proven technology will be far broader in application than

vs RAP unproven technology​

.

2. RSH is a ongoing monitoring & management system; RAP is positioning itself as a diagnostic device - interestingly RSH started it life developing its technology as a diagnostic tool however the previous managements found the pathway through regulatory approval (FDA especially) far too onerous. The FDA and other regulators are paranoid of people "self diagnosing" and will never give OTC approval to sell direct to the consumer. At best there will be a tele-health application however tele-health is taking a lot longer to pick up than people were expecting due to concerns over privacy, accuracy and quality of medical practitioner.

3. RSH is a multi-product (proven products) platform; RAP is a single unproven product - RSH has developed 3 (day-time monitoring, overnight monitoring & ER/In-Hospital/Clinical monitoring) products that will be combined into a truly world-leading and unique monitoring & management platform that will be able to measure wheeze, monitor a patients condition and symptoms 24 hours a day, 7 days a weeks and management the patients treatment and medicine adherence, compliance and efficacy.

4. RSH has developed stand-alone devices: RAP is supposedly developing their technology through a smartphone app (no one has yet seen the product RAP will launch to market) - RSH made the decision to develop the stand alone devices after consultation with users, clinicians and technology providers. RSH decided is was the most effective way to move forward such that they will never be beholden to the smartphone providers and there potentially ability to restrict the embedding and/or use of technology as provided and is proprietary to Apple, Samsung, Huawei etc. There is substantial business risk and ongoing cost associated with using only the phone as the delivery platform as operating systems are regularly & continually updated which requires RAP app to be continually updated, unintended consequences to performance of app not to mention the lifecyle & redundancy of the smartphone (if you believe the technology companies) may not far away (less than 5 years). There is also the commercial decision by RSH to have a stand alone device in markets such as China whereby there is potentially more flexibility to separate hardware and software intellectual property (when RSH launches into China) whereas RAP launches the app in which it has embedded it IP and has no mechanism of protection.

Simply put, RSH technology is proven in many clinical trials and results stating that it can measure the primary symptom of asthma- wheezing. RSH is now well down the path of developing its suite of 3 products for a commercial rollout in 2019. RAP has not proven clinically they can measure cough (yet) and are still trying to ascertain the effectiveness and hence viability of there technology. RAP is not a competitor nor a complementary technology yet and even if trial results prove the technology they will have a long journey to regulatory approval and only potentially a B2B application, not B2C.

I hope this provides a little clarity on the huge opportunity RSH represents with proven technology that is a world leading platform for the ongoing monitoring and management of the symptoms of chronic respiratory disease.